avacincaptad pegol sodium · Astellas · NDA 217225
Izervay
Earliest generic entry, as listed
11 Jul 2034
Blocked by patent: US 11273171, US 11491176, US 12016875. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11273171 | use U-3673 | 11 Jul 2034 |
| US 11491176 | use U-3673 | 11 Jul 2034 |
| US 12016875 | use U-3673 | 11 Jul 2034 |
| US 7579456 | substance | 14 Feb 2027 |
| US 9617546 | substance, use U-3673 | 14 Feb 2027 |
| US 8236773 | use U-3673 | 11 Nov 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217225 · 001 · RLD | solution, intravitreal | EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | 11 Jul 2034 |